RNA-tRNA therapy aims to bypass stop signals to treat multiple genetic diseases
Scientists at the University of Toronto engineered suppressor tRNAs delivered in lipid nanoparticles to bypass premature stop signals, restoring full-length proteins in cystic fibrosis models. A specific chemical modification (m1A) boosted tRNA activity and persistence, while a lung-targeted delivery system (TTP-3) improved tissue reach. Because stop signals occur across many genes, this RNA-based approach could become a disease-agnostic platform, potentially treating numerous genetic disorders, though clinical safety and organ-specific delivery remain key hurdles before use in people.
